Figure 5.

Risk strata distribution using COMPERA 2.0 by medication cohort. (a) A higher proportion of patients with PAH initiated on any PAH therapy were considered high or intermediate‐high risk, as compared to those initiated on prostacyclin (67% vs. 57%). (b, c) Of the patients categorized as high risk by COMPERA 2.0 in the “any PAH medication” cohort who were not on parenteral prostacyclin at baseline, (b) 18% initiated parenteral prostacyclin therapy within 90 days, and (c) 37% of patients in the “prostacyclin‐enriched” cohort not on parenteral prostacyclin therapy at baseline initiated a parenteral prostacyclin within 90 days. Numbers may not add to 100% due to rounding. PAH, pulmonary arterial hypertension; PCY, prostacyclin.